oral-therapeutics
(2)
Syntis Bio wants to put a detour in your daily pill
A mussel-inspired intestinal coating is the unlikely foundation of Syntis Bio’s obesity program. Its daily tablet aims to borrow a metabolic trick from gastric bypass, with early human results and a much longer test still ahead.
Vertero Therapeutics, Inc.
Vertero Therapeutics is a clinical-stage biotechnology company in Woburn, Massachusetts, developing oral small-molecule drugs for neurodegenerative diseases by targeting causative drivers in the body's periphery - primarily the gut - rather than only the brain. Formerly Axial Therapeutics, the company rebranded as Vertero in October 2025. Its lead candidate, VT-5006, is a gut-selective small molecule for Parkinson's disease that targets CsgA, a bacterial protein linked to protein aggregation and neuroinflammation, and is entering Phase 1 trials.